Lineage Cell Therapeutics, Inc. (LCTX) Spending and interest coverage
- R&D / revenue · 12 months: Value 156.82%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 38.75%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 156.82% | Research and development expense / revenue. Period ending 2026-06-30. $20.52M ÷ $13.08M × 100 ≈ 156.82% |
| Stock-based compensation / revenue · 12 months | 38.75% | Share-based compensation / revenue. Period ending 2026-06-30. $5.07M ÷ $13.08M × 100 ≈ 38.75% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 20.52M USD | Research and Development Expense |
| Revenue | 13.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.07M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -26.85M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.52M | $13.08M | $5.07M | $-26.85M | (m) | 156.82% | 38.75% | (m) | (m) |
| 2026-03-31 | $18.85M | $14.78M | $4.71M | $-37.71M | (m) | 127.54% | 31.85% | (m) | (m) |
| 2025-12-31 | $17.73M | $14.56M | $4.75M | $-36.62M | (m) | 121.80% | 32.65% | (m) | (m) |
| 2025-09-30 | $12.91M | $10.82M | $4.97M | $-35.18M | (m) | 119.40% | 45.94% | (m) | (m) |
| 2025-06-30 | $12.81M | $10.91M | $5.10M | $-35.23M | (m) | 117.41% | 46.73% | (m) | (m) |
| 2025-03-31 | $12.58M | $9.56M | $5.13M | $-21.32M | (m) | 131.59% | 53.69% | (m) | (m) |
| 2024-12-31 | $12.47M | $9.50M | $5.08M | $-21.48M | (m) | 131.30% | 53.45% | (m) | (m) |
| 2024-09-30 | $12.96M | $8.72M | $4.82M | $-22.73M | (m) | 148.58% | 55.30% | (m) | (m) |
| 2024-06-30 | $13.53M | $6.19M | $4.76M | $-25.59M | (m) | 218.64% | 76.96% | (m) | (m) |
| 2024-03-31 | $14.53M | $8.00M | $4.77M | $-24.75M | (m) | 181.56% | 59.63% | (m) | (m) |
| 2023-12-31 | $15.71M | $8.95M | $4.64M | $-24.73M | (m) | 175.57% | 51.87% | (m) | (m) |
| 2023-09-30 | $15.90M | $8.77M | $4.54M | $-25.01M | (m) | 181.29% | 51.74% | (m) | (m) |
| 2023-06-30 | $15.76M | $10.52M | $4.26M | $-23.56M | (m) | 149.71% | 40.45% | (m) | (m) |
| 2023-03-31 | $15.18M | $11.85M | $4.21M | $-22.77M | (m) | 128.11% | 35.54% | (m) | (m) |
| 2022-12-31 | $13.99M | $14.70M | $4.29M | $-22.52M | (m) | 95.13% | 29.16% | (m) | (m) |
| 2022-09-30 | $34.66M | $13.96M | $4.25M | $-44.12M | (m) | 248.36% | 30.42% | (m) | (m) |
| 2022-06-30 | $33.88M | $13.23M | $4.40M | $-45.71M | (m) | 256.12% | 33.28% | (m) | (m) |
| 2022-03-31 | $33.51M | $9.19M | $4.09M | $-48.56M | (m) | 364.73% | 44.48% | (m) | (m) |
| 2021-12-31 | $33.91M | $4.34M | $3.52M | $-49.21M | (m) | 781.25% | 81.06% | (m) | (m) |
| 2021-09-30 | $11.74M | $3.53M | $3.10M | $-26.86M | (m) | 332.85% | 87.73% | (m) | (m) |
| 2021-06-30 | $12.50M | $1.83M | $2.45M | $-26.74M | (m) | 683.32% | 134.12% | (m) | (m) |
| 2021-03-31 | $12.37M | (m) | $2.14M | $-26.06M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $12.32M | $1.83M | $2.23M | $-26.45M | (m) | 674.53% | 121.96% | (m) | (m) |
| 2020-09-30 | $13.20M | (m) | $2.35M | $-27.44M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $13.90M | (m) | $2.61M | $-29.13M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $16.33M | (m) | $2.77M | $-33.55M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $17.95M | $3.52M | $3.58M | $-38.88M | (m) | 510.61% | 101.85% | (m) | (m) |
| 2019-09-30 | $18.24M | (m) | $4.97M | $-42.22M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $18.86M | (m) | $5.52M | $-44.15M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $19.98M | (m) | $5.86M | $-42.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $20.95M | $4.99M | $5.40M | $-41.80M | (m) | 420.11% | 108.30% | (m) | (m) |
| 2018-09-30 | $21.87M | $5.23M | $4.43M | $-41.14M | (m) | 418.28% | 84.64% | (m) | (m) |
| 2018-06-30 | $23.55M | $5.93M | $4.09M | $-40.30M | (m) | 396.90% | 68.91% | (m) | (m) |
| 2018-03-31 | $23.46M | $3.77M | $3.89M | $-39.83M | (m) | 622.58% | 103.21% | (m) | (m) |
| 2017-12-31 | $24.02M | $3.46M | $3.93M | $-38.90M | (m) | 694.74% | 113.71% | (m) | (m) |
| 2017-09-30 | $26.34M | $3.54M | $4.55M | $-40.59M | (m) | 743.65% | 128.49% | (m) | (m) |
| 2017-06-30 | $26.20M | $3.35M | $4.29M | $-42.39M | (m) | 781.16% | 127.85% | (m) | (m) |
| 2017-03-31 | $28.87M | $4.24M | $5.60M | $-46.47M | (m) | 680.80% | 132.17% | (m) | (m) |
| 2016-12-31 | $36.11M | $5.92M | $7.95M | $-58.97M | (m) | 609.59% | 134.24% | (m) | (m) |
| 2016-09-30 | $41.88M | $6.30M | (m) | $-69.41M | (m) | 664.67% | (m) | (m) | (m) |
| 2016-06-30 | $46.89M | $7.11M | (m) | $-76.96M | (m) | 659.71% | (m) | (m) | (m) |
| 2016-03-31 | $47.02M | $7.84M | $12.51M | $-76.06M | (m) | 599.30% | 159.45% | (m) | (m) |
| 2015-12-31 | $42.60M | $7.04M | $11.05M | $-65.81M | (m) | 605.51% | 157.05% | (m) | (m) |
| 2015-09-30 | $41.08M | $7.45M | $8.32M | $-58.51M | (m) | 551.18% | 111.68% | (m) | (m) |
| 2015-06-30 | $38.45M | $6.34M | $5.94M | $-53.50M | (m) | 606.57% | 93.77% | (m) | (m) |
| 2015-03-31 | $38.45M | $5.44M | $5.57M | $-53.05M | (m) | 706.68% | 102.34% | (m) | (m) |
| 2014-12-31 | $37.53M | $5.24M | $4.46M | $-50.68M | (m) | 715.83% | 84.98% | (m) | (m) |
| 2014-09-30 | $35.49M | $5.26M | $4.16M | $-65.57M | (m) | 674.94% | 79.18% | (m) | (m) |
| 2014-06-30 | $33.10M | $4.78M | $4.08M | $-63.65M | (m) | 692.06% | 85.26% | (m) | (m) |
| 2014-03-31 | $29.62M | $4.89M | $3.33M | $-58.74M | (m) | 606.15% | 68.10% | (m) | (m) |
| 2013-12-31 | $26.61M | $4.43M | $3.22M | $-55.99M | (m) | 600.08% | 72.57% | (m) | (m) |
| 2013-09-30 | $22.18M | $3.76M | $2.22M | $-33.75M | (m) | 589.28% | 58.89% | (m) | (m) |
| 2013-06-30 | $20.32M | $4.05M | $1.71M | $-29.53M | (m) | 501.45% | 42.08% | (m) | (m) |
| 2013-03-31 | $19.33M | $3.88M | $1.54M | $-27.47M | (m) | 498.59% | 39.65% | (m) | (m) |
| 2012-12-31 | $18.12M | $3.92M | $1.28M | $-25.00M | (m) | 462.71% | 32.76% | (m) | (m) |
| 2012-09-30 | $-10.13M | (m) | $1.38M | $-23.40M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-11.21M | (m) | $1.27M | $-21.67M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-12.47M | $4.16M | $1.24M | $-20.58M | (m) | -299.60% | 29.89% | (m) | (m) |
| 2011-12-31 | $-13.70M | $4.35M | $1.22M | $-18.69M | (m) | -314.59% | 27.96% | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-8.19M | $3.68M | $638.71K | $-9.85M | (m) | -222.57% | 17.35% | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-3.18M | $1.93M | $260.84K | $-3.52M | (m) | -165.27% | 13.55% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |